Q-omics provides the consensus-scored CASTOR1 profile across patient tissues and cancer cell-line models. CASTOR1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CASTOR1 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, CASTOR1 RNA expression shows 16,062 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRP as cancer lineages where CASTOR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASTOR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASTOR1 survival associations across molecular data types. CASTOR1 RNA expression shows survival associations in the most cancer types (19), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASTOR1 RNA expression–survival associations across cancer types. High CASTOR1 expression shows unfavorable associations in ACC and COAD, but favorable associations in UVM, CHOL, LGG and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CASTOR1 RNA expression.
This table summarizes CASTOR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CASTOR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASTOR1 shows lower tumor expression in KIRP, KICH, BRCA and THCA and higher tumor expression in LIHC and CHOL. The KIRP box plot shows higher CASTOR1 RNA expression in normal versus tumor tissue (log2 FC = −1.244, t-test p < 0.001).
This table shows molecular features associated with CASTOR1 in patient tissues and cancer cell lines. In patient samples, CASTOR1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CASTOR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
